Company profile

Robert F. Friel
Incorporated in
Fiscal year end
Former names
Eg&g Inc
IRS number

PKI stock data

FINRA relative short interest over last month (20 trading days) ?


25 Feb 20
7 Apr 20
29 Dec 20


Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 805.5M 706.92M 722.52M 648.74M
Net income 64.5M 58.56M 69.09M 35.41M
Diluted EPS 0.58 0.52 0.62 0.32
Net profit margin 8.01% 8.28% 9.56% 5.46%
Operating income 138.25M 78.66M 91.74M 53.33M
Net change in cash -201.09M 242.95M 15.76M -28.86M
Cash on hand 191.88M 392.97M 150.02M 134.25M
Cost of revenue 364.65M 374.72M 340.93M
Annual (USD) Dec 19 Dec 14
Revenue 2.88B 2.24B
Net income 227.56M 157.78M
Diluted EPS 2.04 1.39
Net profit margin 7.89% 7.05%
Operating income 361.97M 165.01M
Net change in cash 17.06M
Cash on hand 191.88M 174.82M
Cost of revenue 427.27M

Financial data from Perkinelmer earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
16 Mar 20 Michel Vounatsos Common Stock Grant Aquire A 0 250 0 438
16 Mar 20 Michel Vounatsos Common Stock Grant Aquire A 0 188 0 188
18 Feb 20 Tajinder S Vohra Common Stock Payment of exercise Dispose F 95.56 514 49.12K 9,766
10 Feb 20 Michas Alexis P Common Stock Option exercise Aquire M 30.51 75 2.29K 61,691
10 Feb 20 Michas Alexis P NQ Stock Option Common Stock Option exercise Dispose M 30.51 75 2.29K 0
7 Feb 20 Andrew Okun Common Stock Payment of exercise Dispose F 95.6 1,369 130.88K 12,310
7 Feb 20 Andrew Okun Common Stock Payment of exercise Dispose F 95.6 1,391 132.98K 13,679
7 Feb 20 Andrew Okun Common Stock Grant Aquire A 0 3,024 0 15,070
96.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 422 413 +2.2%
Opened positions 60 53 +13.2%
Closed positions 51 68 -25.0%
Increased positions 148 150 -1.3%
Reduced positions 124 129 -3.9%
13F shares
Current Prev Q Change
Total value 596.77B 644.71B -7.4%
Total shares 107.79M 106.41M +1.3%
Total puts 13.14K 19K -30.8%
Total calls 177.8K 60K +196.3%
Total put/call ratio 0.1 0.3 -76.7%
Largest owners
Shares Value Change
N Price T Rowe Associates 19.88M $1.93B +4.5%
Vanguard 12.27M $1.19B +0.9%
Capital Research Global Investors 11.86M $1.15B +13.2%
BLK BlackRock 7.09M $688.52M +1.5%
JHG Janus Henderson 6.54M $634.57M +5.4%
Select Equity 5.69M $552.39B -20.4%
Massachusetts Financial Services 4.96M $481.21M +11.2%
STT State Street 4.43M $430.19M +2.2%
Primecap Management 2.56M $248.22M -1.0%
King Luther Capital Management 2.52M $245M +0.9%
Largest transactions
Shares Bought/sold Change
Select Equity 5.69M -1.46M -20.4%
Capital Research Global Investors 11.86M +1.38M +13.2%
N Price T Rowe Associates 19.88M +859.05K +4.5%
Norges Bank 824.1K +824.1K NEW
Capital International Investors 0 -701.47K EXIT
Massachusetts Financial Services 4.96M +498.04K +11.2%
Citadel Advisors 396.65K -438.15K -52.5%
KBCSF KBC 509.68K +416.64K +447.8%
Fisher Asset Management 66.91K -365.59K -84.5%
JHG Janus Henderson 6.54M +337.2K +5.4%

Financial report summary

  • If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there are uncertainties surrounding the approval of government or industrial funding proposals, or there are unfavorable changes in government regulations, we may see an adverse effect on the results of our business operations.
  • Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.
  • If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.
  • We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, or make acquired businesses or licensed technologies profitable.
  • We may not be successful in adequately protecting our intellectual property.
  • If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
  • If we do not compete effectively, our business will be harmed.
  • Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.
  • A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability.
  • Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
  • The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
  • If we fail to maintain satisfactory compliance with the regulations of the United States Food and Drug Administration and other governmental agencies in the United States and abroad, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil, criminal or monetary penalties.
  • Changes in governmental regulations may reduce demand for our products or increase our expenses.
  • The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
  • Outbreaks of communicable diseases in various parts of China and other countries may materially and adversely affect our business, financial condition and results of operations.
  • Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability.
  • If we do not retain our key personnel, our ability to execute our business strategy will be limited.
  • If we experience a significant disruption in, or breach in security of, our information technology systems or those of our customers, suppliers or other third parties, or cybercrime, resulting in inappropriate access to or inadvertent transfer of information or assets, or if we fail to implement new systems, software and technologies successfully, our business could be adversely affected.
  • We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
  • Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities.
  • Discontinuation, reform, or replacement of LIBOR may adversely affect our variable rate debt.
  • Our results of operations will be adversely affected if we fail to realize the full value of our intangible assets.
  • Our share price will fluctuate.
  • Dividends on our common stock could be reduced or eliminated in the future.
Management Discussion
  • Revenue for fiscal year 2019 was $2,883.7 million, as compared to $2,778.0 million for fiscal year 2018, an increase of $105.7 million, or 4%, which includes an approximate 1% increase in revenue attributable to acquisitions and divestitures and a
  • 2% decrease in revenue attributable to changes in foreign exchange rates. The analysis in the remainder of this paragraph compares segment revenue for fiscal year 2019 as compared to fiscal year 2018 and includes the effect of foreign exchange rate fluctuations, and acquisitions and divestitures. The total increase in revenue reflects an increase in our Diagnostics segment revenue of $52.7 million, or 5%, due to growth in our reproductive health and immunodiagnostics businesses partially offset by unfavorable changes in foreign exchange rates. Our Discovery & Analytical Solutions segment revenue increased by $53.0 million, or 3%, due to an increase of $42.5 million from our life sciences market revenue and an increase of $10.4 million from our applied markets revenue, partially offset by unfavorable changes in foreign exchange rates. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $0.8 million of revenue primarily related to our Diagnostics segment for each of fiscal years 2019 and 2018 that otherwise would have been recorded by the acquired businesses during each of the respective periods.
  • Cost of revenue for fiscal year 2019 was $1,487.6 million, as compared to $1,437.1 million for fiscal year 2018, an increase of approximately $50.6 million, or 4%. As a percentage of revenue, cost of revenue decreased to 51.6% in fiscal year 2019 from 51.7% in fiscal year 2018, resulting in an increase in gross margin of approximately 14 basis points to 48.4% in fiscal year 2019 from 48.3% in fiscal year 2018. Amortization of intangible assets increased and was $61.4 million for fiscal year 2019, as compared to $46.2 million for fiscal year 2018. Stock-based compensation expense was $1.6 million for fiscal year 2019, as compared to $1.5 million for fiscal year 2018. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions added an incremental expense of $21.6 million for fiscal year 2019, as compared to $19.3 million for fiscal year 2018. Acquisition and divestiture-related expenses, contingent consideration and other costs were minimal for fiscal year 2019, as compared to an incremental expense of $0.1 million for fiscal year 2018. In addition to the factors noted above, the overall increase in gross margin primarily the result of mix, price and improved manufacturing and services productivity.
Content analysis ?
H.S. sophomore Avg
New words: Acridinium, alter, anniversary, antigen, ash, automotive, background, Beijing, benchmark, built, captured, cardiac, chemiluminescence, chemiluminescent, children, ChLIA, Cisbio, CKMB, Clarity, Codolet, collagen, compelling, composition, Counter, Creatine, CRP, cTnI, Diode, distinguishing, dried, Duchenne, dystrophy, elaborate, embryo, enrichment, ester, explicitly, extinguishment, FDA, FlexarTM, France, franchise, FT, galactomannoprotein, GenePrism, HaoyuanTM, HBV, HCV, HTRF, IA, identical, identity, implicit, inert, infection, Interbank, intermediary, intolerance, intraperiod, invasive, irrevocably, isoform, iv, IVF, Kinase, launched, LC, lessor, lock, LPC, Lyme, mathematical, Meizheng, mentioned, Microscopic, minute, MM, muscle, muscular, MYO, NaN, NexSAR, obviating, online, orderly, outbreak, particle, path, peak, permission, phase, POC, predominant, principle, proven, Quasar, QuasarTM, quick, RA, rational, repay, respiratory, revolutionary, ROU, salt, SAS, Shandong, Silica, smart, SOFR, SPE, speciation, SPP, spread, strain, stronger, submit, Superflex, SuperflexTM, surface, swap, switching, Symbio, systematic, traditional, Transmission, unclear, upper, verification, verify, wavelength, wear, withdrew
Removed: Abbott, agent, AlliedSignal, assembly, assured, attractive, AxION, Becton, Boston, buyer, CADx, CareFusion, Chairman, Chase, Clarifying, classify, collectability, College, concentrated, context, Corbett, defer, depicting, Dickinson, directed, disposed, disregard, distribute, earliest, element, ensuring, expansion, explain, extension, facilitate, Fairleigh, feet, footage, Friel, fulfillment, good, granting, iCAD, intention, intuitive, IP, JP, Lafayette, Lastly, leased, missing, Morgan, notified, NuVasive, objective, occupied, output, participant, persuasive, PET, prepaid, prohibition, promise, quantitative, reconciling, release, Robert, screen, simultaneously, square, substantive, symbolic, undelivered, VSOE, Xylem